Read by QxMD icon Read

Urology cancer

Girish S Kulkarni, Peter C Black, Srikala S Sridhar, Anil Kapoor, Alexandre R Zlotta, Bobby Shayegan, Ricardo Rendon, Peter Chung, Theodorus Van Der Kwast, Nimira Alimohamed, Yves Fradet, Wassim Kassouf
No abstract text is available yet for this article.
January 31, 2019: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Ahmet M Aydin, Nirmish Singla, Vandana Panwar, Solomon L Woldu, Yuval Freifeld, Christopher G Wood, Jose A Karam, Alon Z Weizer, Jay D Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Andrea Haitel, Marco Roscigno, Christian Bolenz, Karim Bensalah, Mary E Westerman, Arthur I Sagalowsky, Shahrokh F Shariat, Yair Lotan, Aditya Bagrodia, Payal Kapur, Vitaly Margulis, Laura-Maria Krabbe
PURPOSE: To evaluate the prognostic value of BRCA1-associated protein-1 (BAP1) expression in upper tract urothelial carcinoma (UTUC), as BAP1 mutations have been associated with prognostic implications in urologic and non-urologic malignancies. METHODS: We reviewed a multi-institutional cohort of patients who underwent radical nephroureterectomy (RNU) for high-grade UTUC from 1990-2008. Immunohistochemistry (IHC) for BAP1 was performed on tissue microarrays. Staining intensity was graded from 0-3, with BAP1 loss defined as an average intensity of < 1...
February 13, 2019: World Journal of Urology
Lee A Hugar, Samia H Lopa, Jonathan G Yabes, Justin A Yu, Robert M Turner, Mina M Fam, Liam C MacLeod, Benjamin J Davies, Angela B Smith, Bruce L Jacobs
OBJECTIVES: To describe the rate and determinants of palliative care use among Medicare beneficiaries with bladder cancer and encourage a national dialogue on improving coordinated urologic, oncologic, and palliative care in patients with genitourinary malignancies. MATERIALS AND METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients diagnosed with muscle-invasive bladder cancer between 2008-2013. Our primary outcome was receipt of palliative care, defined as the presence of a claim submitted by a Hospice and Palliative Medicine subspecialist...
February 13, 2019: BJU International
Shivashankar Damodaran, Joshua M Lang, David F Jarrard
PURPOSE: Androgen deprivation therapy(ADT) alone has been the standard of care for metastatic hormone sensitive prostate cancer(mHSPC) for the last 75 years. This review focuses on recent trials and mechanisms that highlight a new paradigm, combining ADT with other agents, changing the management of prostate cancer patients with advanced disease. METHODS: A PubMed and Web of Science database search on peer-reviewed literature was performed through January 2018 using the keywords "metastatic hormone sensitive prostate cancer", " metastatic castration sensitive prostate cancer", "docetaxel", "abiraterone" and "senescence in cancer"...
February 7, 2019: Journal of Urology
Hikaru Ihira, Norie Sawada, Taiki Yamaji, Atsushi Goto, Taichi Shimazu, Manami Inoue, Motoki Iwasaki, Shoichiro Tsugane
BACKGROUND: Although physical activity has been reported as a protective factor for kidney and bladder cancer in epidemiological studies, it is not clear. METHODS: In a population-based prospective study of 76,795 Japanese aged 45-74 years, participants were evaluated physical activity by self-administered questionnaire. Hazard ratios (HRs) and 95% confidence intervals (CIs) of the risk of urological cancer were calculated by the Cox proportional hazards models...
February 12, 2019: British Journal of Cancer
Samuel W D Merriel, Liz Hetherington, Andrew Seggie, Joanna T Castle, William Cross, Monique J Roobol, Vincent Gnanapragasam, Caroline M Moore
OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS: A consensus statement was drafted on the basis of three sources of data: systematic literature search of national and international guidelines; data arising from a Freedom of Information (FOI) Act request to UK urology departments regarding their current practice of AS; survey and interview responses from men with localised prostate cancer regarding their experiences and views of AS...
February 11, 2019: BJU International
Julián Oñate-Celdrán, Julián J Arense-Gonzalo, Jaime Mendiola, Paula Samper-Mateo, Carlos Sánchez-Rodríguez, Damián García-Escudero, Marcos Torres-Roca, Marcos Torres-Roca, Olimpia Molina-Hernández, Olimpia Molina-Hernández, Evdochia Adoamnei, Alberto M Torres-Cantero
OBJECTIVE: To evaluate the associationbetween anogenital distance (AGD), as a biomarker ofprenatal androgen milieu, and risk of prostate cancer(PCa). METHODS: A case-control study was conducted on260 men attending a university hospital where theyunderwent physical and andrological examination andcompleted a brief questionnaire. PCa patients were confirmedby biopsy of the tumor. Controls were men withoutPCa attending the urology outpatient clinic for routineexaminations...
January 2019: Archivos Españoles de Urología
Juan Gómez Rivas, Aritz Eguibar Gonzalez, Leonardo Tortolero Blanco, Alfredo Aguilera Bazán, Luis Martínez-Piñeiro, Rafael Sánchez-Salas
OBJECTIVES: Bladder tumors are thesecond highest incidence urological tumor in the adultpopulation. In recent years, new techniques such as photodynamicdiagnosis have arisen in order to improvethe sensitivity for the detection of non muscle invasivebladder cancer (NMIBC). We intend to update the roleof photodynamic diagnosis in the diagnosis of NMIBC,in cases refractory to BCG and as a treatment in therecurrent bladder cancer. MATERIAL AND METHOD: We performed a descriptivestudy and bibliographic review on the usefulness of photratatodynamicdiagnosis in NMIBC, early recurrence andrefractoriness to BCG published in the universal medicalliterature...
January 2019: Archivos Españoles de Urología
Matthew Smith, Chris Parker, Fred Saad, Kurt Miller, Bertrand Tombal, Quan Sing Ng, Martin Boegemann, Vsevolod Matveev, Josep Maria Piulats, Luis Eduardo Zucca, Oleg Karyakin, Go Kimura, Nobuaki Matsubara, William Carlos Nahas, Franco Nolè, Eli Rosenbaum, Axel Heidenreich, Yoshiyuki Kakehi, Amily Zhang, Heiko Krissel, Michael Teufel, Junwu Shen, Volker Wagner, Celestia Higano
BACKGROUND: Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases. We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients. METHODS: We did a randomised, double-blind, placebo-controlled, phase 3 trial at 165 oncology and urology centres in 19 countries...
February 6, 2019: Lancet Oncology
Liang Dong, Richard C Zieren, Yanqing Wang, Theo M de Reijke, Wei Xue, Kenneth J Pienta
Urological malignancies, including prostate cancer, bladder cancer and kidney cancer are major causes of morbidity and mortality worldwide. Because of the high incidence, diversity in biology, and especially direct interaction with urine, urological cancers are an important resource for both scientists and clinicians for novel diagnostic and therapeutic discovery. Extracellular vesicles (EVs) are lipid bilayer encapsulated particles released by cells into the extracellular space. Since EVs work as a safe way to transport important biological information through the whole body, they are now recognized as an important mechanism of cell-cell communication and have opened a new window for us to gain a better understanding of cancer biology, novel diagnostics, and/or therapeutic options...
February 6, 2019: Biochimica et biophysica acta. Reviews on cancer
Louis Potters, Zaker Rana, Lucille Lee, Brett W Cox
INTRODUCTION: This study presents a prospective phase I, IRB-approved dose-escalated stereotactic body radiotherapy (SBRT) trial for prostate cancer (CaP) to assess the impact of dose level on quality of life, toxicity, and clinical outcomes. MATERIALS/METHODS: From 2011-2016, 26 patients with low and intermediate-risk CaP received 40, 45, and 50 Gy in five fractions to the prostate in cohorts of 9, 10, and 7 patients. Self-reported QOL was prospectively measured from the Expanded Prostate Cancer Index Composite (EPIC) and American Urological Association (AUA)...
February 2, 2019: International Journal of Radiation Oncology, Biology, Physics
Mahesh Botejue, Daniel Abbott, John Danella, Claudette Fonshell, Serge Ginzburg, Thomas J Guzzo, Thomas Lanchoney, Bret Marlowe, Jay D Raman, Marc Smaldone, Jeffrey J Tomaszewski, Edouard J Trabulsi, Robert G Uzzo, Adam C Reese
PURPOSE: We describe contemporary active surveillance utilization and variation in a regional prostate cancer collaborative. We identified demographic and disease specific factors associated with active surveillance in men with newly diagnosed prostate cancer. MATERIALS AND METHODS: We analyzed data from the PURC (Pennsylvania Urologic Regional Collaborative), a cooperative effort of urology practices in southeastern Pennsylvania and New Jersey. We determined the rates of active surveillance among men with newly diagnosed NCCN (National Comprehensive Cancer Network®) very low, low or intermediate prostate cancer and compared the rates among participating practices and providers...
January 31, 2019: Journal of Urology
Haifeng Song, Guanyu Kuang, Zhenan Zhang, Binglei Ma, Jie Jin, Qian Zhang
Objective: Growing evidence suggests pretreatment fibrinogen can serve as a prognostic marker in various malignancies. However, there are contradictory results about the prognostic role of fibrinogen in urological cancers. We conducted a meta-analysis to evaluate the association between pretreatment plasma fibrinogen and survival outcomes in urological cancers. Methods: After a systematic search of PubMed and Embase, we included 14 studies in our meta-analysis, and estimated hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS) using a fixed-effect model...
2019: Journal of Cancer
Qi-Zhong Lu, Xiang Li, Jun Ouyang, Jin-Quan Li, Gang Chen
Hyperbaric oxygen therapy (HBOT) has been used as an adjuvant treatment for multiple pathological states, which involves hypoxic conditions. Over the past 50 years, HBOT has been recommended and used in a wide variety of medical conditions, clinically in the treatment of ischemic or nonhealing wounds and radiation-injured tissue, and in the treatment of malignancy. The mechanism of this treatment is providing oxygen under pressure which is higher than the atmosphere thus increasing tissue oxygen concentration...
October 2018: Medical Gas Research
Goro Kasuya, Hiroshi Tsuji, Takuma Nomiya, Hirokazu Makishima, Yasuo Haruyama, Gen Kobashi, Kazuhiko Hayashi, Daniel K Ebner, Tokuhiko Omatsu, Riwa Kishimoto, Shigeo Yasuda, Tatsuo Igarashi, Mototsugu Oya, Koichiro Akakura, Hiroyoshi Suzuki, Tomohiko Ichikawa, Jun Shimazaki, Tadashi Kamada
The aims of this study were to clarify the safety and efficacy of 12-fraction carbon-ion radiotherapy (CIRT) for primary renal cell carcinoma (RCC) and to confirm the recommended dose in a prospective clinical trial. This clinical trial was planned as a non-randomized, open-label, single-center phase I/II study of CIRT monotherapy. The incidence of acute adverse events was the primary endpoint. Dose-limiting toxicities (DLTs) were defined as grade ≥3 skin, gastrointestinal tract, or urologic adverse events...
January 1, 2019: Oncotarget
Carina Jensen, Jesper Carl, Lars Boesen, Niels Christian Langkilde, Lasse Riis Østergaard
PURPOSE: To automatically assess the aggressiveness of prostate cancer (PCa) lesions using zonal-specific image features extracted from diffusion weighted imaging (DWI) and T2W MRI. METHODS: Region of interest was extracted from DWI (peripheral zone) and T2W MRI (transitional zone and anterior fibromuscular stroma) around the center of 112 PCa lesions from 99 patients. Image histogram and texture features, 38 in total, were used together with a k-nearest neighbor classifier to classify lesions into their respective prognostic Grade Group (GG) (proposed by the International Society of Urological Pathology 2014 consensus conference)...
February 3, 2019: Journal of Applied Clinical Medical Physics
Eva Compérat, Justine Varinot, Caroline Eymerit, Gladell P Paner, Donna E Hansel, Mahul B Amin, Julien Moroch
The pTNM stage is one of the most important parameters in the handling of tumor patients. The pathologist plays a major role in the determination of the stage. The classifications undergo an evolution according to the state of art. The TNM system is used worldwide and allows to precise the tumor (T) and lymph node stage and the presence of distant metastasis. This system helps to stratify patient groups and determine their prognosis. In 2017, the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) published their 8th edition...
January 30, 2019: Annales de Pathologie
Matthew J Ziegelmann, Jason P Joseph, Amy E Glasgow, Mark D Tyson, Raymond W Pak, Halena M Gazelka, Ashton L Schatz, Bradley C Leibovich, Elizabeth B Habermann, Matthew T Gettman
OBJECTIVE: To describe postoperative opioid prescribing practices in a large cohort of patients undergoing urological surgery. PATIENTS AND METHODS: We identified 11,829 patients who underwent 21 urological surgical procedures at 3 associated facilities from January 1, 2015, through December 31, 2016. After converting opioids to oral morphine equivalents (OMEs), prescribing patterns were compared within and across procedures. Subgroup analysis for opioid-naive patients (those without a history of long-term opioid use) was performed...
February 2019: Mayo Clinic Proceedings
Enrico Checcucci, Daniele Amparore, Stefano De Luca, Riccardo Autorino, Cristian Fiori, Francesco Porpiglia
Over the past few years several new technologies have become available for the management of PCa. The implementation of robotic surgery allowed an unprecedented refinement of surgical techniques, and the RARP procedure is constantly evolving. Nowadays research is mainly focused towards a "tailored" case-specific surgical approach that might allow to achieve PCa control while preserving urinary continence and erectile function. Therefore, in contemporary urology era, several new tools have been introduced to optimize surgical planning, to aid surgical navigation, and to refine surgical execution...
January 28, 2019: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
Jiangfeng Li, Haixiang Shen, Haiyun Xie, Yufan Ying, Ke Jin, Huaqing Yan, Song Wang, Mingjie Xu, Xiao Wang, Xin Xu, Liping Xie
Genomic imprinting has been found to be involved in human physical development and several diseases. The DLK1-DIO3 imprinted domain is located on human chromosome 14 and contains paternally expressed protein-coding genes ( DLK1, RTL1, DIO3 ) and numerous maternally expressed ncRNA genes ( MEG3, MEG8 , antisense RTL1 , miRNAs, piRNAs, and snoRNAs). Emerging evidence has implicated that dysregulation of the DLK1-DIO3 imprinted domain especially the imprinted ncRNAs is critical for tumor progressions. Multiple miRNAs and lncRNAs have been investigated in urological cancers, of which several are transcribed from this domain...
2019: Cancer Management and Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"